Inactive Instrument

Mindset Pharma Inc.

MSET

CA60268M1023

Biotechnology & Medical Research

Mindset Pharma Inc. Generates Promising in Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing

January 06, 2021 at 10:08 am EST

Mindset Pharma Inc. announced that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds are exhibiting positive in vitro characteristics.

Latest news about Mindset Pharma Inc.

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc..	23-10-26	CI
Mindset Pharma Agrees to be Bought by Otsuka Pharmaceutical	23-08-31	MT
Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. for CAD 75.9 million.	23-08-30	CI
Mindset Pharma Inc. Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder	23-06-22	CI
Mindset Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-30	CI
Mindset Pharma Inc. Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds	23-04-26	CI
Mindset Pharma CEO, James Lanthier, Issues Letter Discussing Expansion into Non-Hallucinogenic Therapeutics	23-03-28	MT
Reunion Neuroscience Filed Lawsuit Against Mindset Pharma	23-03-14	MT
Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. Complete First Sale of Pharmaceutical Grade Psilocybin into Growing Australian Market Via Sales Partnership	23-03-06	CI
Mindset Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-23	CI
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs	23-02-02	CI
Mindset Pharma Receives USPTO Allowance For Application Expanding Composition of Matter for Family 1 Psilocybin Analogs	23-02-02	MT
Mindset Pharma Inc. Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate	23-01-20	CI
Mindset Pharma Receives US Patent Application Allowance For Lead Candidate MSP-1014, Tryptamine Prodrug Candidates	23-01-20	MT
Mindset Pharma Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-29	CI
Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for Sale and Distribution of Pharmaceutical Grade Psilocybin	22-11-16	MT
Mindset Pharma Inc. and Pharmala Biotech Holdings Inc. Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin	22-11-16	CI
Mindset Pharma Presents Poster At Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, Its Psilocybin-Like Lead Drug Candidate	22-11-14	CI
Mindset Pharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-10-26	CI
Mindset Pharma Inc. Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio	22-10-05	CI
Mindset Pharma Provides Strategic Intellectual Property License to NYSE-listed Cybin	22-09-27	MT
Cybin IRL Limited Obtains Exclusive License to A Novel Catalog of Psychedelic-Based Compounds from Mindset Pharma Inc	22-09-27	CI
Mindset Pharma Inc. Provides Strategic Intellectual Property License to Cybin Inc	22-09-27	CI
Mindset Pharma Receives Advice from UK Regulator Facilitating Advancement of Phase 1 Clinical Trial Plan For MSP-1014	22-09-14	MT
Mindset Pharma Inc. Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014	22-09-14	CI

Mindset Pharma Inc. is a Canada-based drug discovery and development company focused on creating optimized and patentable psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. The Company is developing various families of psychedelic compounds, as well as a process to chemically synthesize psilocybin in addition to its own proprietary compounds. The Company, through the McQuade Center, covers multiple drug development programs. The Company has developed 4 families of next-generation psychedelics with differentiated characteristics. The Company's portfolio consists of macrodosing and microdosing. Its macrodosing includes Family 1/MSP-1014, Family 2, and Family 4. The MSP-1014 is a new chemical entity that incorporates a conjugated amplifier into a psilocybin-like structure to create an effective drug. The Company's Family 3 is a long-acting next-generation psychedelic drug positioned for micro-dosing.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q3 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research